dc.contributor.author | Eren, Gülnihan | |
dc.contributor.author | Kupik, Osman | |
dc.date.accessioned | 2022-10-24T08:25:22Z | |
dc.date.available | 2022-10-24T08:25:22Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Eren, G., & Kupik, O. (2022). Necrosis onstaging 18F FDG PET/CT is associated with worse progression-free survival in patients with stage IIIB non-small cell lung cancer. Journal of cancer research and therapeutics, 18(4), 971–976. https://doi.org/10.4103/jcrt.jcrt_1215_21 | en_US |
dc.identifier.issn | 1998-4138 | |
dc.identifier.uri | https://doi.org/10.4103/jcrt.jcrt_1215_21 | |
dc.identifier.uri | 0973-1482 | |
dc.identifier.uri | https://hdl.handle.net/11436/6826 | |
dc.description.abstract | Objective: The presence of pathological necrosis in the tumor is known to be a factor indicating worse survival. Our study defined necrosis in staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with stage IIIB non-small-cell lung cancer (NSCLC) to investigate whether this is a poor prognostic marker. Methodology: A total of 77 patients with NSCLC were evaluated. To evaluate necrosis on 18F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no FDG uptake on PET and PET/CT fusion images. If SUVmax was less than blood pool SUVmax and showed significantly less attenuation [10 to 30 Hounsfield units (HUs)] than surrounding tissue on low-dose correlative CT with non-intravenous contrast, we defined it as necrotic (PETNECROSIS). We evaluated the relationship of SUVmax, tumor size, and PETNECROSIS with progression-free survival (PFS) using a Cox proportional hazard regression model. Results: A PFS analysis was performed on 16 patients treated with standard chemoradiotherapy (CRT) regimen. Tumor size <_42 mm versus > 42 mm (P = 0.044, HR: 6.103, 95 CI%: 1.053-35.358) and PETNECROSIS presence/absence (P = 0.027, HR: 6.719, 95 CI%: 1.245-36.264) were independent predictors for PFS. Patients with tumor size <_42 mm and PET(NECROSIS )absence were associated with higher 1-year PFS rate than patients with tumor size > 42 mm and PETNECROSIS presence (86% vs. 63.5% P = 0.005 and 87.5% vs. 29%, P = 0.001, respectively). Conclusion: PETNECROSIS is helpful to distinguish the patients who would suffer worse survival in stage IIIB NSCLC. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wolters Kluwer Medknow Publications | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Fluorodeoxyglucose | en_US |
dc.subject | Non-small cell lung cancer | en_US |
dc.subject | Positron emission tomography | en_US |
dc.subject | Nercosis | en_US |
dc.subject | Survival | en_US |
dc.title | Necrosis onstaging 18F FDG PET/CT is associated with worse progression-free survival in patients with stage IIIB non-small cell lung cancer | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Eren, Gülnihan | |
dc.contributor.institutionauthor | Kupik, Osman | |
dc.identifier.doi | 10.4103/jcrt.jcrt_1215_21 | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 971 | en_US |
dc.identifier.endpage | 976 | en_US |
dc.relation.journal | Journal of Cancer Research and Therapeutics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |